Hormone – Talk Bio

Teva Launches First Generic GLP-1 for Weight Loss Amid Ongoing Market Developments

1 week ago talkbio0Tagged Approved, Generic Drugs, Glucagon-Like Peptide 1, liraglutide, Saxenda, Teva, United States Food and Drug Administration, Weight-Loss Agents

generic GLP-1; Teva; liraglutide; Saxenda; FDA approval; weight loss drugs

Obesity biotech Alveus raises ~$160M Series A to advance MariTide‑like GLP‑1/GIPR drug and amylin pipeline

2 weeks ago talkbio0Tagged * * New Rhein Healthcare Investors, * * Sanofi Capital, ALV-100, ALV-200, Alveus Therapeutics, Amylin, Andera Partners, Antagonist muscle action, GIPR gene, MariTide-like, Metabolic Diseases, Obesity, Omega Funds, Product containing glucagon-like peptide 1 receptor agonist (product), Series

Alveus Therapeutics; obesity biotech; $160 million Series A; ALV-100; MariTide-like; GLP-1 receptor agonist; GIPR antagonist; amylin; ALV-200; obesity drugs; metabolic diseases; Sanofi Capital; New Rhein Healthcare Investors; Andera Partners; Omega Funds

Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported

2 months ago talkbio0Tagged Abnormal, aspects of adverse effects, Dysesthesia, Eli, Eli Lilly, Gastric Inhibitory Polypeptide, glucagon, Glucagon-Like Peptide 1, Obesity, Phase III, retatrutide, safety signal, sense of, Therapeutic tactile stimulation, triple agonist, triple hormone receptor agonist, TRIUMPH-4, Weight Loss

Eli Lilly; retatrutide; triple agonist; triple hormone receptor agonist; GLP-1; GIP; glucagon; obesity; weight loss; TRIUMPH-4; Phase III; dysesthesia; abnormal sense of touch; safety signal; side effects

PBMs and FTC Battle in Court Over In-House Insulin Pricing Challenge Intensifies

2 months ago talkbio0Tagged administrative proceedings, antitrust lawsuit, Caremark Rx, drug affordability, Express Scripts, Insulin, PBMs, Pricing, rebate schemes, United States Federal Trade Commission

PBMs; FTC; insulin pricing; rebate schemes; antitrust lawsuit; administrative proceedings; drug affordability; Caremark Rx; Express Scripts; OptumRx

FDA Moves to Remove Black Box Warnings from Menopausal Hormone Therapies

3 months ago talkbio0Tagged Black Box Warning, estrogens, Hormone replacement therapy, Hormone Therapy, labeling change, Menopausal symptom, Menopause, Progestins, United States Food and Drug Administration, women 's health

FDA; menopause; hormone therapy; black box warning; HRT; estrogen; progestogen; labeling change; women’s health; menopausal symptoms

Lilly Prepares Amylin-Based Obesity Drug Eloralintide for Phase III After Strong Weight Loss Results

3 months ago talkbio0Tagged Agonist, Amylin, Clinical Development, Eli, Eli Lilly, Eloralintide, Obesity Drug, Phase 3 Clinical Trials, Weight Loss

Eli Lilly; eloralintide; amylin agonist; obesity drug; Phase III trial; weight loss; clinical development

Eli Lilly to Invest $3 Billion in New European Factory for Weight-Loss Pill Orforglipron

3 months ago talkbio0Tagged advanced manufacturing, eli lilly, European market, global supply chain, Leiden Bio Science Park, Manufacturing Facilities, Netherlands, obesity pill, orforglipron, Product containing glucagon-like peptide 1 receptor agonist (product)

Eli Lilly; Orforglipron; obesity pill; Leiden Bio Science Park; Netherlands; GLP-1 receptor agonist; manufacturing facility; European market; advanced manufacturing; global supply chain

Lilly Commits $1.2 Billion to Expand GLP-1 Pill Manufacturing Facility in Puerto Rico

3 months ago talkbio0Tagged Carolina, eli lilly, expansion, Investments, Manufacturing, Oral Medicine, orforglipron, pharmaceutical production, Product containing glucagon-like peptide 1 receptor agonist (product), Puerto Rico, supply chain, United States

Eli Lilly; Puerto Rico; GLP-1 receptor agonist; orforglipron; manufacturing expansion; oral medicines; investment; Carolina; pharmaceutical production; U.S. supply chain

Terns Ditches Obesity Pill After Phase 2 Letdown, Shifts Focus to Cancer Pipeline

3 months ago talkbio0Tagged liver enzyme elevation, Metabolic Diseases, Myeloid Leukemia, Chronic, Neoplasms, Obesity Drug, Phase 2 trial, Product containing glucagon-like peptide 1 receptor agonist (product), TERN-601, TERN-701, Terns, Weight Loss

Terns Pharmaceuticals; TERN-601; obesity drug; GLP-1 receptor agonist; Phase 2 trial; weight loss; liver enzyme elevation; oncology; TERN-701; chronic myeloid leukemia (CML); metabolic disease

Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales

3 months ago talkbio0Tagged Appointments, Arginine Vasopressin-Neurophysin II Preproprotein, board of directors, commercialization, global sales, Health care facility, Inspira Technologies, Johnson & Johnson, Leadership, Mike Hershkovitz

Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors